Cipla, Dr Reddy’s, and Lupin, are among pharma companies which got notice for launching drugs in the market without taking prior go-ahead from the national drug pricing regulator, the Government informed the Parliament recently.
The drugs include those used for treating conditions such as diabetes, inflammation and chronic hepatitis C among others.
In a written reply in Lok Sabha Minister for the Chemicals & Fertilizers D V Sadananda Gowda said, “Companies that introduced a total of 22 drugs without prior approval of the National Pharmaceutical Pricing Authority (NPPA) have been issued notices.”
While Alembic Pharmaceuticals has introduced two drugs — Resync 75/50 mg and Trivogo tablet without prior nod from NPPA, Biocon has introduced Blisto Trio 0.2/500/2 mg and Blisto Trio 0.2/500/1 mg, he said. Cipla has introduced Hepcvel tablets and Dr Reddy’s Laboratories has introduced Resof total 400/100 mg, without taking the prior permission, Gowda said.
The other companies who launched the drugs without getting the prior nod from the national pharmaceutical pricing authority include — Sanofi India Ltd, Hetero Healthcare, Cadila Healthcare, Ipca Laboratories, Boehringer Ingelheim India and Kemwell Biopharma, Unichem Laboratories, Wockhardt and Medibios Laboratories, the minister said.
“The NPPA regularly takes action against such companies as per provisions of the Drugs (Prices Control) Order, 2013 (DPCO) which has been issued under the Essential Commodities Act, 1955,” he added.